|Jeff Robinson, CEO of Wuhan, Provides Key Updates and Outlook in a New Audio Interview with SmallCapVoice.com|
|By GLOBE NEWSWIRE|
|Friday, 22 May 2020 03:00|
AUSTIN, Texas, May 22, 2020 (GLOBE NEWSWIRE)
AUSTIN, Texas, May 22, 2020 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (SCV) and Wuhan General Group, Inc. (OTC PINK: WUHN) (the "Company" and "Wuhan"), announced today that a new audio interview with the Company is now available.
The interview featuring an overview of WUHN’s current news and moves can be heard at https://www.smallcapvoice.com/tag/wuhn/.
Jeff Robinson, CEO of Wuhan, called in to SmallCapVoice.com to go over the business model and markets that his Company operates in. Wuhan is currently positioning itself to become a major player in the estimated 146.4 billion dollars medical CBD (cannabidiol) space as well as the promising psilocybin medical health sector.
In the interview Robinson stated, “We are one of only a handful of companies in the world working psilocybin and conducting clinical trials. On the CBD side, once the lockdown, due to the pandemic, ends in South Africa, our products will be on store shelves. That would be the products in the Dr. AnnaRx and Medspresso brands. These are really exciting times for our company. We are thankful for the opportunity to share our story with our shareholders and the SmallCapVoice.com listening audience."
Dr. AnnaRx™ is a wholly-owned international trademark of MJ MedTech, used for the branding of its line of by-products and medical research with our high-end Broad-Spectrum Cannabidiol (CBD), is of the highest purity and potency and includes other beneficial cannabinoids, terpenes and molecules, that help promote healthy body and skin care, under the umbrella of Dr. Anna Leralta recommendations.
Wuhan General Group, Inc. is a client of StockVest. StockVest's team of top Influencers introduces publicly traded companies to a wide audience of investors from around the globe, helping public companies attain maximum market awareness resulting in increased trading volume, a broadened shareholder base and increased share valuations.
About Wuhan General Group, Inc.
Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under the Dr. AnnaRx™ and Medspresso™ brands. In addition, its new wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from mental illness, Alzheimer's and Parkinson's. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.
Wuhan General Group, Inc.
Publicly traded company (OTC Pink: WUHN)
SmallCapVoice.com, Inc. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies, small cap and micro-cap stocks build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, podcasts, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks in which they are interested. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTCMarkets. To learn more about SmallCapVoice.com and its services, please visit https://www.smallcapvoice.com/small-cap-stock-otc-investor-relations-financial-public-relations/.
Socialize with SmallCapVoice and their clients at;
Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements. For further information contact:
E-mail: [email protected]
Stuart T. Smith